When was Orano Med founded?

Orano Med was founded in 2009 and raised its 1st funding round 14 years after it was founded.

Where is Orano Med located?

Orano Med is headquartered in Plano, United States.

How many employees does Orano Med have?

As of Sep 30, 2026, the latest employee count at Orano Med is 236.

Is Orano Med a funded company?

Orano Med is a funded company, having raised a total of $***** in its 1st and only funding round, a Grant (prize money) round on Dec 28, 2023.

When was the latest funding round of Orano Med?

Orano Med's latest funding was a $***** Grant (prize money) round on Dec 28, 2023, with participation from 1 investor.

Where does Orano Med rank among its competitors?

Orano Med ranks 869th amongst 3410 active competitors, of which 1135 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Orano Med?

Orano Med's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Orano Med - 2026 Company Profile, Funding & Competitors

Company Details

Developing targeted cancer therapies using Lead-212 radioisotope for alphatherapy. The company focuses on developing a new generation of targeted therapies against cancer, leveraging the unique properties of Lead-212, a rare alpha-emitting radioisotope with significant cytotoxic properties. This approach, known as targeted alphatherapy, aims to deliver radiation directly to cancer cells, minimizing damage to healthy tissue. The company has preclinical laboratories dedicated to alphatherapy development and an industrial platform for Lead-212 production. They are conducting clinical trials to evaluate the effectiveness of their therapies. The company's work contributes to the field of radiopharmaceuticals and precision medicine, offering a potential solution for cancer treatment. The company is involved in scientific publications and research in the field of cancer treatment.

Website: www.oranomed.com
Social
Email ID: *****@oranomed.com
Phone Number: +1 **********
Part Of

Key Metrics

Founded Year

2009

Location

Plano, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Dec 28, 2023, $*****

Investors

Economy And Finance

Ranked

869^th among 3410 active competitors

Employee Count

236 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3119 more

View Orano Med's full profile

Orano Med has raised funding over 1 round. Its latest funding round was a Grant (prize money) round on Dec 28, 2023 for $*****. 1 investor participated in its latest round. Orano Med has 1 institutional investor.

Here is the list of recent funding rounds of Orano Med:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 28, 2023	5418234	Grant (prize money)	1037969	6312453	9836370	5855034

Access funding benchmarks and valuations. Sign up today!

View details of Orano Med's funding rounds and investors

Orano Med's employee count trend

Orano Med has 236 employees as of Sep 26. Here is Orano Med's employee count trend over the years:

Uncover Orano Med's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Orano Med include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Orano Med, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Leaps by Bayer, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
869th	Orano Med 2009, Plano (United States), Funding Raised	Developing targeted cancer therapies using Lead-212 radioisotope for alphatherapy	-	Economy And Finance	43/100